Learn

Eating well in menopause, and the treatments your clinician may offer.

Two halves of the same conversation. What you eat is in your hands every day. Prescription treatments are decided with your doctor or nurse practitioner. Both deserve a plain explanation, so here is what the evidence says about each, with the sources linked.

Part one: food

Start with the pattern, not a single food

A Mediterranean-style pattern is the best-studied option in midlife: vegetables, fruit, beans and lentils, whole grains, olive oil and fish, with processed food kept to a minimum. The European Menopause and Andropause Society reviewed the research and found that long-term adherence is linked to better heart health, better bone density, lower risk of cognitive decline and lower mortality, and may help blood pressure, cholesterol, blood sugar and mood. Most of that evidence is observational, so the statement says "may" rather than "will." The evidence for symptom relief is weaker: a 2024 cross-sectional study of 207 Australian women found no link between how closely they followed the diet and how severe their symptoms were. In plain terms, this pattern fits general heart and bone health guidance; it is not a proven hot-flash treatment.

Calcium and vitamin D: the numbers

Bone loss speeds up after menopause. The U.S. Department of Health and Human Services Office on Women's Health advises women 51 and older to get 1,200 mg of calcium a day, and 600 IU of vitamin D a day (800 IU from age 71). Food sources include dairy or fortified plant milks, canned fish with the bones, tofu, leafy greens and fortified cereals. Vitamin D is hard to get from food alone. Ask your clinician whether your diet, a supplement or testing should change.

Protein, spread through the day

Age-related muscle loss is a real concern in midlife, and adequate protein with resistance exercise can support muscle health. Some expert guidance for older adults suggests about 1.0 to 1.2 grams of protein per kilogram of body weight a day; for a 70 kg (154 lb) woman that is roughly 70 to 84 grams. Needs vary with health and activity, and the menopause-specific evidence is still limited, so treat this as a sensible target to discuss, not a rule.

Fiber, fruit and vegetables

Some studies associate plant-rich eating with milder symptoms and healthier aging, though results are not consistent enough to call it a treatment. Fiber-rich foods can support bowel regularity. Persistent bowel changes, unexplained weight change or symptoms that suggest a blood glucose problem deserve a clinician's attention, not a diet change alone.

Soy: a good food, an unproven remedy

Soy foods (tofu, edamame, soy milk) provide protein; calcium varies by product. Whether soy helps hot flashes is disputed. In a 2012 meta-analysis, 13 trials of soy isoflavone extracts showed about a 20.6 percent reduction in hot-flash frequency compared with placebo, but The Menopause Society's 2023 review judged the evidence mixed and does not recommend soy foods or extracts as a treatment for hot flashes. Soy can be part of a balanced diet; it is not a treatment.

Caffeine, alcohol and spicy food

In a Mayo Clinic survey of 1,806 women, caffeine was associated with more bothersome hot flashes and night sweats after menopause. It was a cross-sectional study, so it cannot show that caffeine caused the symptoms. Alcohol and spicy food are commonly reported triggers, but The Menopause Society notes there are no trials showing that avoiding triggers treats hot flashes. If you suspect something affects you, changing one thing at a time for a week or two is a reasonable way to find out; it is not a treatment.

What the evidence does not support

The Menopause Society's 2023 statement lists dietary changes, supplements, herbal remedies, trigger avoidance, cooling techniques, exercise, yoga, mindfulness and acupuncture among the approaches not recommended as treatments for hot flashes, because the trials do not show a reliable effect. That does not make good food or exercise pointless; it means they are for your long-term health. If hot flashes are bothersome, a licensed prescriber can discuss the options below.

Part two: treatments your clinician may offer

These are decided with a licensed prescriber, such as your doctor or nurse practitioner. My role is to help you understand them and prepare for that conversation.

Hormone therapy

The Menopause Society's 2022 position statement calls hormone therapy the most effective treatment for hot flashes and night sweats and for the vaginal and urinary symptoms of menopause, and it prevents bone loss and fracture. For women under 60 or within 10 years of menopause onset who have bothersome symptoms or a bone-loss indication and no contraindications, the Society says the benefit-risk balance is favorable. Your own history still decides it. Starting hormone therapy later, or after 60, is less favorable because the absolute risks of heart disease, stroke, blood clots and dementia are higher. Dose, type, route (pill, patch, gel) and duration are individual decisions, reviewed over time. The products are not interchangeable: if you have a uterus and take systemic estrogen, a progestogen is usually added to protect the uterine lining, and low-dose vaginal estrogen is a separate decision.

In November 2025 the FDA began removing the boxed warnings about heart disease, breast cancer and probable dementia from menopausal hormone therapy labels, and on 12 February 2026 it approved the first six revised labels. Information about cardiovascular and breast cancer risk still appears elsewhere in the labels of systemic products, and the boxed warning about endometrial cancer remains for systemic estrogen-alone products. Your clinician will weigh your own history, including breast cancer, clots and liver disease, and risks differ by product and route. The FDA and ACOG also advise against routinely using custom-compounded "bioidentical" hormones in place of FDA-approved products, which include bioidentical options.

Non-hormonal prescriptions for hot flashes

If hormone therapy is not right for you, The Menopause Society's 2023 statement recommends these, each backed by randomized trials:

• Fezolinetant (Veozah), FDA-approved in May 2023, and elinzanetant (Lynkuet), approved in October 2025. A nonhormonal class (neurokinin receptor antagonists) that acts on the brain's temperature regulation. In December 2024 the FDA added a boxed warning to Veozah for rare but serious liver injury: liver blood tests are required before starting and at intervals during treatment, and symptoms such as yellowing skin or eyes, dark urine, nausea or itching need prompt attention.
• Certain antidepressants (SSRIs and SNRIs), at doses used for hot flashes; a low-dose form of paroxetine is FDA-approved for this. Tell the prescriber about every medicine you take: paroxetine, for example, can interfere with tamoxifen.
• Gabapentin, which may also help nighttime symptoms.
• Oxybutynin, a bladder medicine with evidence for hot flashes. It can cause dry mouth, constipation and blurred vision, and clinicians weigh its effects on memory with long-term use, so raise any memory concerns.

The same statement recommends two non-drug approaches with good trial evidence: cognitive behavioral therapy, which mainly reduces how much hot flashes bother you, and clinical hypnosis. It also lists weight loss and a procedure called stellate ganglion block among the options, with weaker evidence.

Vaginal dryness, pain with sex and urinary symptoms

These are common and treatable, and women often do not raise them. For milder symptoms the first step is a regular vaginal moisturizer and a lubricant with sex. For moderate to severe symptoms, the 2020 statement (published by the North American Menopause Society, now The Menopause Society) names low-dose vaginal estrogen, vaginal DHEA (prasterone), oral ospemifene and, where otherwise appropriate, systemic estrogen as effective prescription options. Low-dose vaginal estrogen has low absorption into the bloodstream and is considered separately from systemic therapy, but personal history still matters; women with a history of breast cancer should make this decision with their oncologist involved.

Bone health beyond diet

If a bone density scan shows osteoporosis or high fracture risk, calcium, vitamin D and exercise are not the whole conversation: the Endocrine Society's guideline lists bisphosphonates as first-line medicines, with other options for selected women. Ask whether a scan is due.

Part three: bringing it to your appointment

• Bring a diary of symptoms, sleep, and what you ate and drank, if you find it useful.
• Ask: "Given my history, am I a candidate for hormone therapy? If not, which non-hormonal option fits me?"
• Ask about bone health: "Do I need a bone density scan, and how much calcium and vitamin D should I take?"
• Raise vaginal or urinary symptoms directly; they will not be assumed.
• Ask what benefits, side effects, monitoring and follow-up apply to the option being considered.

The free doctor-visit guide has these questions as a printable checklist.

Sources

1. European Menopause and Andropause Society, "The Mediterranean diet and menopausal health: an EMAS position statement," Maturitas, 2020. maturitas.org
2. U.S. Department of Health and Human Services, Office on Women's Health, "Menopause and your health." womenshealth.gov
3. Mayo Clinic Press, "How much protein do you really need after menopause?" mcpress.mayoclinic.org
4. Taku K. et al., "Extracted or synthesized soybean isoflavones reduce menopausal hot flash frequency and severity," Menopause, 2012. PubMed
5. The Menopause Society, "The 2023 nonhormone therapy position statement." menopause.org
6. Faubion S. et al., "Caffeine and menopausal symptoms: what is the association?" Menopause, 2015. journals.lww.com
7. The Menopause Society, "The 2022 hormone therapy position statement." PubMed
8. U.S. Food and Drug Administration, press announcement on removal of boxed warnings from menopausal hormone therapy, November 2025. fda.gov
9. U.S. Food and Drug Administration, drug safety communication on Veozah (fezolinetant) and serious liver injury, December 2024. fda.gov
10. North American Menopause Society (now The Menopause Society), "The 2020 genitourinary syndrome of menopause position statement." PDF
11. U.S. Food and Drug Administration, "FDA approves labeling changes for menopausal hormone therapy products," 12 February 2026. fda.gov
12. American College of Obstetricians and Gynecologists, Clinical Consensus on compounded bioidentical menopausal hormone therapy, 2023. acog.org
13. Endocrine Society, clinical practice guideline on osteoporosis in postmenopausal women. endocrine.org
14. "Dietary interventions and nutritional strategies for menopausal health: a mini review," 2025. PubMed Central

Sources last checked 5 October 2026.